BVCF
VC Fund
Shanghai, China
BVCF is a VC fund in Shanghai focused on Biotechnology and Health Care. In 2005, Bvcf Became The First International Private Equity Firm To Come To China Dedicated To Investing In China'S Life Sciences. Dr. Zhi Yang Founded The Firm With The Vision That It Would Be The Key Investor In China'S Life Sciences Golden Age By Being First And Bringing Unmatched Domain Expertise.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 42%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries BVCF invests in
Stages BVCF invests in
Countries BVCF invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 14 (58%)
- Health Care 11 (46%)
- Pharmaceutical 9 (38%)
- Medical 7 (29%)
- Therapeutics 4 (17%)
Stage
- Series A 9 (38%)
- Venture - Series Unknown 4 (17%)
- Seed 2 (8%)
- Series B 2 (8%)
- Series C 2 (8%)
Country
- China 11 (46%)
- United States 6 (25%)
- Germany 1 (4%)
- Iceland 1 (4%)
- Singapore 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Zhi Yang
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 6 | Find email | |
Mengqi Chen
CFO
|
CFO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Drug Farm
|
Drug Farm is a China and US-based biotech developing innovative treatments targeting innate immunity for HBV, cancer, and autoimmune diseases. Drug Farm's unique IDInVivo platform combines breakthrough technologies in genetics and AI to discover new treatments. | $55M / Series D / Jul 13, 2026 | |
Qiselian Biotechnology
|
Qiselian Biotech focuses on personalized cell therapy and anti-aging. Based on the new generation of induced pluripotent stem cell (iPSC) technology, it develops innovative products and services for autologous cell therapy, regenerative medicine and health management. | Seed / Apr 18, 2025 | |
Vivalink
|
VivaLnk is a provider of connected healthcare solutions for in-patient and remote patient monitoring. The company’s portfolio includes wearable medical grade devices and data analytics applications that continuously monitor the health and well-being of individuals.The company's vision is to improve the quality and accessibility of healthcareworldwide by combining technology, data, and analytics into an integrated solution.In 2014, VivaLNK introduced eSkin which represented the first-of-its-kind breathable thin film substrate with integrated circuits and sensors designed for long term wearable use. | Venture - Series Unknown / Nov 09, 2023 | |
Cellenkos
|
Cellenkos is a clinical-stage biotech company focused on the development and commercialization of transformative novel allogeneic Treg cell therapies to treat autoimmune and inflammatory disorders. | $15M / Series A / Nov 04, 2021 | |
Oculis
|
The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops. | $57M / Series C / May 04, 2021 | |
|
Drug Farm
|
Drug Farm is a China and US-based biotech developing innovative treatments targeting innate immunity for HBV, cancer, and autoimmune diseases. Drug Farm's unique IDInVivo platform combines breakthrough technologies in genetics and AI to discover new treatments. | $56M / Series A / Feb 09, 2021 | |
Boan Biotech
|
Boan Biotech is a biopharmaceutical company developing therapeutic antibodies with a focus on key therapeutic areas including oncology, metabolism, autoimmunity, and ophthalmology. | $105.6M / Series A / Jan 05, 2021 | |
GenEros Biopharma
|
GenEros Biopharma is a biopharmaceutical company that develops autoimmune and anti-inflammation therapeutics. | Venture - Series Unknown / Jan 01, 2021 | |
Seinda
|
Seinda develops a point-of-care diagnosis platform for ophthalmic diagnosis and treatment. Seinda is committed to establishing an open ophthalmic omics platform, conducting molecular mechanism research on eye diseases, developing innovative diagnosis and treatment products, meeting clinical needs, gaining market premium, and building a world-classChinese brand. | Seed / Sep 23, 2020 | |
BioNTech
|
BioNTech is a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. It contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. | $325M / Series B / Jul 09, 2019 | |
| See all 24 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does BVCF invest in?
BVCF invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Venture - Series Unknown stage. Most of the 24 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact BVCF?
Public channels for BVCF include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BVCF?
The team at BVCF includes Zhi Yang (Founder & Managing Partner) and Mengqi Chen (CFO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
